The study's authors warned that excess deaths may continue to rise if states don't learn any lessons from the last year. 

The impact on patients over the age of 65 has been undeniable. 

The medication, a PCSK9 inhibitor, was already an approved therapy for adult patients with cardiovascular disease.

The study's authors tracked the health of more than 134,000 individuals from 21 countries for nearly a decade. 

Itchhaporia, an interventional cardiologist, most recently served as the ACC's vice president. 

The findings, published in JAMA Cardiology, confirm that dapagliflozin is a safe, effective treatment option for patients with heart failure with reduced ejection fraction.

The new AI tool can be used alongside GE Healthcare’s full line of Venue ultrasound systems, including the new Venue Fit. 

Radiologists should take note of these findings as the drug's popularity and legalization continue to climb.